The Canadian HIV Quit Smoking Trial: Tackling the Co-morbidities of Depression and Cardiovascular Disease in HIV+ Smokers (CANQUIT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Ottawa Hospital Research Institute
Sponsor:
Collaborators:
Canadian Institutes of Health Research (CIHR)
CIHR Canadian HIV Trials Network
Information provided by (Responsible Party):
Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier:
NCT01800019
First received: February 25, 2013
Last updated: January 10, 2014
Last verified: January 2014

February 25, 2013
January 10, 2014
January 2014
January 2015   (final data collection date for primary outcome measure)
Smoking Status [ Time Frame: at week 48 ] [ Designated as safety issue: No ]
The primary study end-point will be seven-day self-reported abstinence, and four week continuous abstinence rates at week 48, confirmed by expired carbon monoxide levels measured using a piCO+ Smokerlyzer (Smoke free defined as exhaled CO < 10 ppm). Study participants who are lost to follow-up (e.g., study drop-outs and those unavailable for follow-up) will be considered as smokers for the purposes of outcome analyses.
Same as current
Complete list of historical versions of study NCT01800019 on ClinicalTrials.gov Archive Site
  • Smoking Status: self report [ Time Frame: quit date, weeks 4,8,12,16,20,24 and 48 ] [ Designated as safety issue: No ]

    Seven-day point-prevalence, and 4-week continuous abstinence(if time interval permits), assessed by self-report and by expired carbon monoxide levels measured using a piCO+ Smokerlyzer.

    In addition, self-reported 4-week continuous abstinence rates (CAR) will be reported.

  • Smoking status: CO expired [ Time Frame: randomization, quit date, 4, 8, 12, 16, 20, 24 ] [ Designated as safety issue: No ]
    Smoke free status will be objectively measured by exhaled CO levels (<10ppm) with a Bedfont Smokerlyzer instrument.
  • Smoking cessation treatment integrity and patient satisfaction [ Time Frame: Baseline through Week 48 ] [ Designated as safety issue: Yes ]

    Study Medication: Adherence to NRT and varenicline will be assessed by participant self-reported adherence to medication at each study visit.

    Counseling Intervention: Each clinic site will have an HIV clinic health care provider who will be trained in administering the standardized HIV quit smoking intervention.

    Program Satisfaction Form will be completed by all study participants at the end of the study. At post-quit dates, treatment adherence will be assessed by a self-report measure of the amount of NRT or varenicline taken, number of cigarettes smoked in the previous 7 days, and marked changes in mood.

    Study coordinator will assess rates of discontinuation of varenicline or NRT. Participants who discontinue varenicline or NRT will still be followed according to the original schedule.

  • Behavioral-Psychosocial [ Time Frame: Baseline to Week 48 ] [ Designated as safety issue: Yes ]
    • The Minnesota Nicotine Withdrawal Scale
    • The Center for Epidemiological Studies Depression Scale
    • Smoking Self-Efficacy Questionnaire
    • EuroQol(EQ-5D)This scale is a brief, standardized, generic measure of HR-QOL that provides a 5-item profile of patient function and a global health state rating
    • Beck Depression Inventory
    • Experiences in Close Relationships
    • Stages of Change Questionnaire
    • Adherence to Treatment Questionnaire
    • Life Events Questionnaire
    • Use of Cessation Resources Survey
  • Cardiovascular Parameters [ Time Frame: From baseline through 48 weeks ] [ Designated as safety issue: No ]

    The following parameters will be compared:

    1. Weight
    2. Height
    3. Waist circumference (defined by Heart and Stroke Foundation)
    4. Blood pressure
  • Immune Function [ Time Frame: 12, 24, and 48 weeks ] [ Designated as safety issue: No ]

    Changes in:

    1. CD4-T-lymphocyte count and percentage
    2. HIV viral load
    3. CD8-T-lymphocyte count and percentage
  • Smoking Status: self report [ Time Frame: Baseline, quit date, weeks 4,8,12,16,20,24 and 48 ] [ Designated as safety issue: No ]

    Seven-day point-prevalence, and 4-week continuous abstinence(if time interval permits), assessed by self-report and by expired carbon monoxide levels measured using a piCO+ Smokerlyzer.

    In addition, self-reported 4-week continuous abstinence rates (CAR) will be reported.

  • Smoking status: CO expired [ Time Frame: baseline, quit date, 4, 8, 12, 16, 20, 24 ] [ Designated as safety issue: No ]
    Smoke free status will be objectively measured by exhaled CO levels (<10ppm) with a Bedfont Smokerlyzer instrument.
  • Smoking cessation treatment integrity and patient satisfaction [ Time Frame: Baseline through Week 48 ] [ Designated as safety issue: Yes ]

    Study Medication: Adherence to NRT and varenicline will be assessed by participant self-reported adherence to medication at each study visit.

    Counseling Intervention: Each clinic site will have an HIV clinic health care provider who will be trained in administering the standardized HIV quit smoking intervention.

    Program Satisfaction Form will be completed by all study participants at the end of the study. At post-quit dates, treatment adherence will be assessed by a self-report measure of the amount of NRT or varenicline taken, number of cigarettes smoked in the previous 7 days, and marked changes in mood.

    Study coordinator will assess rates of discontinuation of varenicline or NRT. Participants who discontinue varenicline or NRT will still be followed according to the original schedule.

  • Behavioral-Psychosocial [ Time Frame: Baseline to Week 48 ] [ Designated as safety issue: Yes ]
    • The Minnesota Nicotine Withdrawal Scale
    • The Center for Epidemiological Studies Depression Scale
    • Smoking Self-Efficacy Questionnaire
    • Quality of Life: Short-Form-12 Health Survey
    • Beck Depression Inventory
    • Experiences in Close Relationships
    • Stages of Change Questionnaire
    • Adherence to Treatment Questionnaire
    • Life Events Questionnaire
    • Use of Cessation Resources Survey
  • Cardiovascular Parameters [ Time Frame: From baseline through 48 weeks ] [ Designated as safety issue: No ]

    The following parameters will be compared:

    1. Weight
    2. Height
    3. Waist circumference (defined by Heart and Stroke Foundation)
    4. Blood pressure
  • Immune Function [ Time Frame: 12, 24, and 48 weeks ] [ Designated as safety issue: No ]

    Changes in:

    1. CD4-T-lymphocyte count and percentage
    2. HIV viral load
    3. CD8-T-lymphocyte count and percentage
Not Provided
Not Provided
 
The Canadian HIV Quit Smoking Trial: Tackling the Co-morbidities of Depression and Cardiovascular Disease in HIV+ Smokers
The Canadian HIV Quit Smoking Trial: Tackling the Co-morbidities of Depression and Cardiovascular Disease in HIV+ Smokers

The objectives of this trial are:

Primary objectives:

  1. To determine among HIV+ individuals whether varenicline or NRT is more effective at helping individuals remain abstinent from smoking tobacco.
  2. To determine among HIV+ individuals whether varenicline or NRT has the lowest side-effect profile.
  3. To determine if the HIV tailored Quit Smoking Counselling Intervention, plus smoking cessation drug therapy, improves smoking cessation rates compared to smoking cessation drug therapy alone with usual care.

Secondary objective:

1. To determine whether the use of varenicline/NRT is safe in HIV+ patients who exhibit depressive symptoms.

Hypothesis:

That varenicline will result in higher quit smoking rates and that NRT will result in a lower side effect profile. Further, the HIV tailored quit smoking intervention will result in higher rates of smoking cessation over and above the pharmacological treatment alone. And finally, varenicline will be safe to use for HIV + individuals who exhibit depressive symptoms.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
  • HIV
  • Smoking Cessation
  • Drug: Nicotine Replacement Therapy (NRT)
    Other Names:
    • Nico-Derm®
    • Nicoderm
    • the patch
    • Nicorette®
    • the gum
  • Drug: Varenicline
    Other Name: Champix
  • Behavioral: HIV Tailored Quit Smoking Counseling

    A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.

    People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24.

    Other Name: Ottawa Model for Smoking Cessation
  • Active Comparator: NRT arm

    Drug: Nicotine Replacement Therapy (Nico-Derm® and Nicorette®)

    Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study baseline, and withdrawal symptoms.

    Mode of Administration: Transdermal Patch

    Duration of Treatment: up to 24 Weeks

    Additionally, participants will be provided with a supply of short-acting nicotine gum in order to supplement their long acting NRT patch regimen.

    Individuals who smoke their first cigarette more than 30 minutes after waking are advised to use the 2 mg NRT gum. Participants who smoke their first cigarette within 30 minutes of waking will be advised to use the 4 mg NRT gum. Both NRT gum dosages will be recommended for use on an ad lib basis to address cravings and/or withdrawal symptoms, up to a maximum of 12 pieces of NRT gum per day.

    Intervention: Drug: Nicotine Replacement Therapy (NRT)
  • Active Comparator: NRT and HIV Tailored Quit Smoking Counseling

    Drug: Nicotine Replacement Therapy (Nico-Derm®)

    Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study randomization and withdrawal symptoms.

    Mode of Administration: Transdermal Patch

    Duration of Treatment: up to 24 Weeks

    HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed.

    Interventions:
    • Drug: Nicotine Replacement Therapy (NRT)
    • Behavioral: HIV Tailored Quit Smoking Counseling
  • Active Comparator: Varenicline (VR) Arm

    Drug: Varenicline (Champix®)

    Doses: 0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period

    Mode of Administration: Oral

    Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)

    Intervention: Drug: Varenicline
  • Active Comparator: Varenicline (VR) and HIV Tailored Quit Smoking Counseling

    Drug: Varenicline (Champix®)

    0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period

    Mode of Administration: Oral

    Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)

    Intervention: HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed.

    Interventions:
    • Drug: Varenicline
    • Behavioral: HIV Tailored Quit Smoking Counseling
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
256
October 2015
January 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. HIV positive
  2. Adult (aged 18 or older)
  3. Current smoker (more than 5 cigarettes per day)
  4. Willing to set a date to quit smoking within the next 2-4 weeks
  5. Currently on ART with an undetectable HIV viral load
  6. Able to read/speak English or French
  7. Able to provide written, informed consent as approved by the Ottawa Health Science Network Research Ethics Board and REBs at participating HIV clinic sites

Exclusion Criteria:

  1. Contraindications to nicotine replacement therapy such as allergy to adhesive, serious cardiac arrhythmias (e.g., tachycardia), or vasospastic disease (e.g., Buerger's disease, Prinzmetal's variant angina)
  2. Contraindications to varenicline such as hypersensitivity to varenicline or to any ingredient in the formulation or component of the container.
  3. Reported previous severe intolerances to nausea or gastrointestinal symptoms.
  4. Pregnant, lactating or planning to become pregnant during the study period or refuses a serum beta-HCG test.
  5. Current severe renal impairment or currently taking Cimetidine
  6. Previous or current seizure disorder and/or is taking anti-epileptic drugs
  7. Psychosis and/or is taking anti-psychotic drugs
  8. Diagnosed with severe major depressive episode requiring hospitalization within the past 12 months, previous psychiatric inpatient admission for any cause within the past 12 months, suicide attempt within the past 12 months active or current suicidal ideations as assessed by the BDI-II.
  9. Current use of bupropion, varenicline or any nicotine replacement therapy.
  10. Use of substances (e.g., crack cocaine) that would interfere with a participant's ability to adhere to the study schedule; determined by site coordinator's discretion.
Both
18 Years and older
No
Contact: Louise Balfour, PhD 613-737-8037 lbalfour@toh.on.ca
Canada
 
NCT01800019
2011824-01H, CTN 269
Yes
Ottawa Hospital Research Institute
Ottawa Hospital Research Institute
  • Canadian Institutes of Health Research (CIHR)
  • CIHR Canadian HIV Trials Network
Principal Investigator: Louise Balfour, PhD Ottawa Hospital Research Institute
Ottawa Hospital Research Institute
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP